ClinicalTrials.gg
RecruitingNCT06832410Updated Mar 23, 2026

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

A Phase 3 interventional study of Biological/Vaccine in Type 1 Diabetes and Kidney Transplant, sponsored by Vertex Pharmaceuticals Incorporated. Recruiting at 7 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Planned enrollment
1,059th of 1,242
10 · median 40
Started
2025
with 64 others
Phase 3
147 of 1,458
10 open now
Primary completion
2026-09
later than 44 of 258 live
Registered
1,350th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 1,059th largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 65 that started in 2025, is one of 147 in phase 3, reaches primary completion later than 44 of the 258 other live ones, and was the 1,350th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

186 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.

03

Conditions studied

  • Type 1 Diabetes
  • Kidney Transplant
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence
  • Taking a stable regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks
  • Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study

Key Exclusion Criteria:

  • Prior islet cell transplant, organ transplant (other than kidney transplant), or cell therapy, except prior pancreatic graft that failed within the first 4 weeks
  • Participants had >1 kidney transplant procedure

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    VX-880

    Biological: Biological/Vaccine

Interventions

  • BiologicalBiological/Vaccine

    Drug page: Biological Products

    Infused into the hepatic portal vein.

    Also known as: Zimislecel, Formerly known as STx-02

06

What researchers measure

Primary outcomes

  1. Proportion of Participants who are Insulin Independent

    Time frame: At 1 year After VX-880 infusion

Secondary outcomes

  1. Proportion of participants who achieve insulin independence and are insulin independent 12 months later

    Time frame: 1 year after achieving insulin independence

  2. Change from Baseline in glycosylated hemoglobin (HbA1c)

    Time frame: Baseline, At 1 year After VX-880 infusion

  3. Proportion of Participants who Maintain Insulin Independence for at least 1 year

    Time frame: From VX-880 infusion to End of Study (up to 2 years)

  4. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Signing of informed consent to End of Study (up to 2 years)

07

Study locations

7 of 7 sites recruiting
  • Perelman Center for Advanced Medicine - Endocrinology
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Montefiore Clinical and Translational Research Center - Endocrinology
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
  • UW University Hospital - Endocrinology
    Madison, Wisconsin 53792, United States
    Recruiting
  • Toronto General Hospital - Endocrinology
    Toronto, Canada
    Recruiting
  • Vancouver General Hospital - Gordon and Leslie Diamond Health Care Centre
    Vancouver, Canada
    Recruiting
  • King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology
    Riyadh, Saudi Arabia
    Recruiting
  • King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology
    Riyadh, Saudi Arabia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Sep 2026, 17 months after the start.

Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 17 months is close to that.

Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 18, 2025
StartActual
Mar 31, 2025
Primary completionEst.
Sep 17, 2026
CompletionEst.
Sep 17, 2027
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06832410
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Mar 31, 2025
Primary completion
Sep 17, 2026 (estimated)
Completion
Sep 17, 2027 (estimated)
Last update
Mar 23, 2026

Study contacts

Medical Information
Contact
medicalinfo@vrtx.com
617-341-6777

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Biological Products

Start the discussion